Vericel (FRA:ATQP) Total Liabilities : €134.4 Mil (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Vericel Total Liabilities?

Vericel's Total Liabilities for the quarter that ended in Dec. 2024 was €134.4 Mil.

Vericel's quarterly Total Liabilities declined from Jun. 2024 (€124.36 Mil) to Sep. 2024 (€119.77 Mil) but then increased from Sep. 2024 (€119.77 Mil) to Dec. 2024 (€134.42 Mil).

Vericel's annual Total Liabilities increased from Dec. 2022 (€76.21 Mil) to Dec. 2023 (€117.11 Mil) and increased from Dec. 2023 (€117.11 Mil) to Dec. 2024 (€134.42 Mil).

Vericel Total Liabilities Historical Data

The historical data trend for Vericel's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Total Liabilities Chart

Vericel Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

58.65

64.82

76.21

117.11

134.42

Vericel Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															117.11	112.94	124.36	119.77	134.42

Vericel Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vericel's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	48.023	+	(85.561	+	0.83699999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	134.4

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	413.25	-	278.828
	=	134.4

Vericel's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	48.023	+	(85.561	+	0.83699999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	134.4

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	413.25	-	278.828
	=	134.4

Vericel Total Liabilities Related Terms

Thank you for viewing the detailed overview of Vericel's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vericel Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (FRA:ATQP) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VCEL:USA ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Headlines

No Headlines